



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Pharmacology

**ESPS manuscript NO:** 22765

**Title:** Adalimumab and pharmacokinetics: impact on the clinical prescription for inflammatory bowel disease.

**Reviewer's code:** 00037816

**Reviewer's country:** Japan

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2015-10-06 01:06

**Date reviewed:** 2015-10-08 16:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

In this manuscript, authors reviewed the factors influencing Adalimumab pharmacokinetics and their clinical impact of IBD. Minor comments Authors should add the table that shows the factors influencing Adalimumab response. Page 4 Inter-patient variability: Could you show the reason why patients with ulcerative colitis seemed to have faster clearance than CD patients? Page 9, line 14-17 Change ADA to Adalimumab.